MDT · Medtronic plc
← all insidersElectromedical & Electrotherapeutic Apparatus · Listed on NYSE
Open-market insider flow over 30d · 90d · 180d · 365d · filter in table · CSV · JSON
Open-market trades1
Distinct insiders1
Bought$0
Sold$257.9K
Net flow$-257.9K
Recent filings
How to read this
- Filed
- Date the Form 4 was filed with the SEC. Insiders must file within 2 business days of the trade.
- Ticker
- The issuer's stock symbol. Select it to open that company's insider-activity page.
- Issuer
- The company whose shares were traded.
- Sector
- The issuer's industry (SEC SIC classification). Select a value to filter to that sector.
- Insider
- The reporting person: an officer, director, or 10% owner. Select a name to see all of their trades.
- Role
- The insider's relationship to the company: director, officer, or 10% owner.
- Code
- SEC transaction code describing the kind of transaction. Full official definitions are under “Transaction codes” below. A dot marks an open-market trade (P/S), the highest-conviction signal.
- Side
- Direction of the trade, from the filing's Acquired (A) ▲ / Disposed of (D) ▼ field: a buy or a sell.
- 10b5-1
- Trade made under a pre-arranged Rule 10b5-1 plan: scheduled in advance, not a discretionary decision (generally lower signal).
- Shares
- Number of shares in this transaction.
- Price
- Reported price per share. Blank for grants, gifts, and other trades with no stated price.
- Value
- Transaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ for their impact).
- Owned after
- Form 4 column “Amount of Securities Beneficially Owned Following Reported Transaction(s)”: shares the insider held (directly or indirectly) immediately after this trade.
- Own Δ
- How much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing.
- Co. Δ
- Change in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake. Based on the latest reported shares outstanding; blank when unavailable.
- D/I
- Form 4 column “Ownership Form: Direct (D) or Indirect (I)”. Indirect holdings (for example, through a trust, fund, or family member) are detailed in the filing's “Nature of Indirect Beneficial Ownership.”
- Lag
- Days from the trade date to the filing date (Form 4 is due within 2 business days).
Transaction codes
Verbatim from the SEC's General Instructions for Forms 3, 4 and 5.
- P
- Open market or private purchase of non-derivative or derivative security
- S
- Open market or private sale of non-derivative or derivative security
- A
- Grant, award or other acquisition pursuant to Rule 16b-3(d)
- D
- Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
- F
- Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
- M
- Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
- G
- Bona fide gift
- C
- Conversion of derivative security
- X
- Exercise of in-the-money or at-the-money derivative security
- J
- Other acquisition or disposition (describe transaction)
| Filed ↓Date the Form 4 was filed with the SEC (due within 2 business days of the trade). | Insider | Role | CodeSEC transaction code describing the kind of transaction. See “How to read this” above for the official SEC definition of each code. The dot marks an open-market trade (P/S). | SideDirection of the trade: a buy (acquired ▲) or a sell (disposed ▼). | Shares | PriceReported price per share. Blank for trades with no stated price. | ValueTransaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ). | Owned afterShares the insider held (directly or indirectly) immediately after this trade. | Own ΔHow much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing. | Co. ΔChange in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake in the company. Based on the latest reported shares outstanding; blank when unavailable. | Link to SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-24 | Marinaro Michael | Officer (EVP, Pres MedSurg and Americas) | F | ▼ sell | 1,0840 | $92.30 | $100.1K | 116,336 | −0.9% | −<0.01% (now <0.01%) | filing |
| 2026-08-04 | Blomquist Denise L. | Officer (Chief Accounting Officer) | A | ▲ buy | 1,366→ 1,366 Ordinary Shares | — | — | 1,366 | — | — | filing |
| 2026-08-04 | Blomquist Denise L. | Officer (Chief Accounting Officer) | A | ▲ buy | 2,337→ 2,337 Ordinary Shares | — | — | 2,337 | — | — | filing |
| 2026-08-04 | Blomquist Denise L. | Officer (Chief Accounting Officer) | A | ▲ buy | 2,3370 | — | — | 16,998 | +16% | +<0.01% (now <0.01%) | filing |
| 2026-08-04 | Blomquist Denise L. | Officer (Chief Accounting Officer) | F | ▼ sell | 2120 | $85.39 | $18.1K | 14,661 | −1% | −<0.01% (now <0.01%) | filing |
| 2026-08-04 | Walter Matthew R. | Officer (SVP, Chief HR Officer) | A | ▲ buy | 40,973→ 40,973 Ordinary Shares | — | — | 40,973 | — | — | filing |
| 2026-08-04 | Walter Matthew R. | Officer (SVP, Chief HR Officer) | A | ▲ buy | 14,421→ 14,421 Ordinary Shares | — | — | 14,421 | — | — | filing |
| 2026-08-04 | Walter Matthew R. | Officer (SVP, Chief HR Officer) | A | ▲ buy | 5,7690 | — | — | 39,928 | +17% | +<0.01% (now <0.01%) | filing |
| 2026-08-04 | Walter Matthew R. | Officer (SVP, Chief HR Officer) | F | ▼ sell | 1,6750 | $85.39 | $143.0K | 34,159 | −5% | −<0.01% (now <0.01%) | filing |
| 2026-08-04 | Thompson Kweli | Officer (EVP & President, Neuroscience) | A | ▲ buy | 49,167→ 49,167 Ordinary Shares | — | — | 49,167 | — | — | filing |
| 2026-08-04 | Thompson Kweli | Officer (EVP & President, Neuroscience) | A | ▲ buy | 17,306→ 17,306 Ordinary Shares | — | — | 17,306 | — | — | filing |
| 2026-08-04 | Thompson Kweli | Officer (EVP & President, Neuroscience) | A | ▲ buy | 6,9230 | — | — | 35,390 | +24% | +<0.01% (now <0.01%) | filing |
| 2026-08-04 | Thompson Kweli | Officer (EVP & President, Neuroscience) | F | ▼ sell | 1,7390 | $85.39 | $148.5K | 28,467 | −6% | −<0.01% (now <0.01%) | filing |
| 2026-08-04 | Pieton Thierry | Officer (EVP & Chief Financial Officer) | A | ▲ buy | 81,945→ 81,945 Ordinary Shares | — | — | 81,945 | — | — | filing |
| 2026-08-04 | Pieton Thierry | Officer (EVP & Chief Financial Officer) | A | ▲ buy | 28,842→ 28,842 Ordinary Shares | — | — | 28,842 | — | — | filing |
| 2026-08-04 | Pieton Thierry | Officer (EVP & Chief Financial Officer) | A | ▲ buy | 11,5370 | — | — | 49,645 | +30% | +<0.01% (now <0.01%) | filing |
| 2026-08-04 | Quinn Michelle | Officer (EVP, GC and Secretary) | A | ▲ buy | 45,070→ 45,070 Ordinary Shares | — | — | 45,070 | — | — | filing |
| 2026-08-04 | Quinn Michelle | Officer (EVP, GC and Secretary) | A | ▲ buy | 15,863→ 15,863 Ordinary Shares | — | — | 15,863 | — | — | filing |
| 2026-08-04 | Quinn Michelle | Officer (EVP, GC and Secretary) | A | ▲ buy | 6,3460 | — | — | 26,721 | +31% | +<0.01% (now <0.01%) | filing |
| 2026-08-04 | Martha Geoffrey | Director, Officer (Chairman and CEO) | A | ▲ buy | 273,150→ 273,150 Ordinary Shares | — | — | 273,150 | — | — | filing |
| 2026-08-04 | Martha Geoffrey | Director, Officer (Chairman and CEO) | A | ▲ buy | 295,002→ 295,002 Ordinary Shares | — | — | 295,002 | — | — | filing |
| 2026-08-04 | Martha Geoffrey | Director, Officer (Chairman and CEO) | A | ▲ buy | 103,831→ 103,831 Ordinary Shares | — | — | 103,831 | — | — | filing |
| 2026-08-04 | Martha Geoffrey | Director, Officer (Chairman and CEO) | A | ▲ buy | 41,5330 | — | — | 327,866 | +15% | +<0.01% (now 0.03%) | filing |
| 2026-08-04 | Martha Geoffrey | Director, Officer (Chairman and CEO) | F | ▼ sell | 15,8100 | $85.39 | $1.35M | 286,333 | −5% | −<0.01% (now 0.02%) | filing |
| 2026-08-04 | Marinaro Michael | Officer (EVP, Pres MedSurg and Americas) | A | ▲ buy | 77,848→ 77,848 Ordinary Shares | — | — | 77,848 | — | — | filing |
| 2026-08-04 | Marinaro Michael | Officer (EVP, Pres MedSurg and Americas) | A | ▲ buy | 27,400→ 27,400 Ordinary Shares | — | — | 27,400 | — | — | filing |
| 2026-08-04 | Marinaro Michael | Officer (EVP, Pres MedSurg and Americas) | A | ▲ buy | 46,1470 | — | — | 117,420 | +65% | +<0.01% (now <0.01%) | filing |
| 2026-08-04 | Marinaro Michael | Officer (EVP, Pres MedSurg and Americas) | A | ▲ buy | 10,9600 | — | — | 71,273 | +18% | +<0.01% (now <0.01%) | filing |
| 2026-08-04 | Marinaro Michael | Officer (EVP, Pres MedSurg and Americas) | F | ▼ sell | 3,3560 | $85.39 | $286.6K | 60,313 | −5% | −<0.01% (now <0.01%) | filing |
| 2026-08-04 | KIIL HARRY SKIP | Officer (EVP & President Cardiovascular) | A | ▲ buy | 65,556→ 65,556 Ordinary Shares | — | — | 65,556 | — | — | filing |
| 2026-08-04 | KIIL HARRY SKIP | Officer (EVP & President Cardiovascular) | A | ▲ buy | 23,074→ 23,074 Ordinary Shares | — | — | 23,074 | — | — | filing |
| 2026-08-04 | KIIL HARRY SKIP | Officer (EVP & President Cardiovascular) | A | ▲ buy | 9,2300 | — | — | 43,669 | +27% | +<0.01% (now <0.01%) | filing |
| 2026-08-04 | KIIL HARRY SKIP | Officer (EVP & President Cardiovascular) | F | ▼ sell | 3,0740 | $85.39 | $262.5K | 34,439 | −8% | −<0.01% (now <0.01%) | filing |
| 2026-07-29 | Quinn Michelle | Officer (EVP, GC and Secretary) | F | ▼ sell | 2,0690 | $86.88 | $179.8K | 20,375 | −9% | −<0.01% (now <0.01%) | filing |
| 2026-07-09 | Walter Matthew R. | Officer (SVP, Chief HR Officer) | S | ▼ sell10b5-1 | 3,1020 | $83.15 | $257.9K | 35,694 | −8% | −<0.01% (now <0.01%) | filing |
| 2026-06-09 | KIIL HARRY SKIP | Officer (EVP & President Cardiovascular) | S | ▼ sell | 2280 | $80.45 | $18.3K | 37,227 | −0.6% | −<0.01% (now <0.01%) | filing |
| 2026-06-09 | KIIL HARRY SKIP | Officer (EVP & President Cardiovascular) | S | ▼ sell | 3,9610 | $80.44 | $318.6K | 37,455 | −10% | −<0.01% (now <0.01%) | filing |
| 2026-06-08 | Walter Matthew R. | Officer (SVP, Chief HR Officer) | F | ▼ sell | 2,8400 | $83.32 | $236.6K | 38,689 | −7% | −<0.01% (now <0.01%) | filing |
| 2026-06-08 | Martha Geoffrey | Director, Officer (Chairman and CEO) | F | ▼ sell | 41,9360 | $83.32 | $3.49M | 301,163 | −12% | −<0.01% (now 0.02%) | filing |
| 2026-06-08 | Marinaro Michael | Officer (EVP, Pres MedSurg and Americas) | F | ▼ sell | 7,4710 | $83.32 | $622.5K | 63,122 | −11% | −<0.01% (now <0.01%) | filing |
| 2026-06-08 | KIIL HARRY SKIP | Officer (EVP & President Cardiovascular) | F | ▼ sell | 6,8170 | $83.32 | $568.0K | 41,416 | −14% | −<0.01% (now <0.01%) | filing |
| 2026-06-08 | Blomquist Denise L. | Officer (Chief Accounting Officer) | F | ▼ sell | 2370 | $83.32 | $19.7K | 14,737 | −2% | −<0.01% (now <0.01%) | filing |
| 2026-05-28 | Walter Matthew R. | Officer (SVP, Chief HR Officer) | M | ▼ sell | 8,449→ 8,449 Ordinary Shares | — | — | 0 | — | — | filing |
| 2026-05-28 | Walter Matthew R. | Officer (SVP, Chief HR Officer) | M | ▲ buy | 9,1490 | — | — | 41,529 | +28% | +<0.01% (now <0.01%) | filing |
| 2026-05-28 | Wall Brett A. | Officer (EVP & Pres Neuroscience) | M | ▼ sell | 24,214→ 24,214 Ordinary Shares | — | — | 0 | — | — | filing |
| 2026-05-28 | Wall Brett A. | Officer (EVP & Pres Neuroscience) | M | ▲ buy | 26,9070 | — | — | 82,183 | +49% | +<0.01% (now <0.01%) | filing |
| 2026-05-28 | Martha Geoffrey | Director, Officer (Chairman and CEO) | M | ▼ sell | 85,461→ 85,461 Ordinary Shares | — | — | 0 | — | — | filing |
| 2026-05-28 | Martha Geoffrey | Director, Officer (Chairman and CEO) | M | ▲ buy | 94,9630 | — | — | 343,099 | +38% | +<0.01% (now 0.03%) | filing |
| 2026-05-28 | Marinaro Michael | Officer (EVP, Pres MedSurg and Americas) | M | ▼ sell | 17,093→ 17,093 Ordinary Shares | — | — | 0 | — | — | filing |
| 2026-05-28 | Marinaro Michael | Officer (EVP, Pres MedSurg and Americas) | M | ▲ buy | 18,9940 | — | — | 70,593 | +37% | +<0.01% (now <0.01%) | filing |
| 2026-05-28 | KIIL HARRY SKIP | Officer (EVP & President Cardiovascular) | M | ▼ sell | 14,517→ 14,517 Ordinary Shares | — | — | 0 | — | — | filing |
| 2026-05-28 | KIIL HARRY SKIP | Officer (EVP & President Cardiovascular) | M | ▲ buy | 15,1950 | — | — | 48,233 | +46% | +<0.01% (now <0.01%) | filing |
| 2026-05-28 | Blomquist Denise L. | Officer (Chief Accounting Officer) | M | ▼ sell | 1,621→ 1,621 Ordinary Shares | — | — | 0 | — | — | filing |
| 2026-05-28 | Blomquist Denise L. | Officer (Chief Accounting Officer) | M | ▲ buy | 1,7120 | — | — | 14,974 | +13% | +<0.01% (now <0.01%) | filing |
| 2026-05-04 | Walter Matthew R. | Officer (SVP, Chief HR Officer) | F | ▼ sell | 350 | $80.00 | $2.8K | 32,380 | −0.1% | −<0.01% (now <0.01%) | filing |
| 2026-04-29 | NABEL ELIZABETH G | Director | F | ▼ sell | 2070 | $81.90 | $17.0K | 19,584 | −1% | −<0.01% (now <0.01%) | filing |
| 2026-04-29 | NABEL ELIZABETH G | Director | A | ▲ buy | 2,1110 | — | — | 19,791 | +12% | +<0.01% (now <0.01%) | filing |
| 2026-04-29 | Powell Kendall J | Director | F | ▼ sell | 2070 | $81.90 | $17.0K | 51,380 | −0.4% | −<0.01% (now <0.01%) | filing |
| 2026-04-29 | Powell Kendall J | Director | A | ▲ buy | 2,1110 | — | — | 51,587 | +4% | +<0.01% (now <0.01%) | filing |
| 2026-04-29 | Lofton Kevin E | Director | F | ▼ sell | 2070 | $81.90 | $17.0K | 10,140 | −2% | −<0.01% (now <0.01%) | filing |
| 2026-04-29 | Lofton Kevin E | Director | A | ▲ buy | 2,1110 | — | — | 10,347 | +26% | +<0.01% (now <0.01%) | filing |
| 2026-04-29 | Lewis Gregory P | Director | F | ▼ sell | 2070 | $81.90 | $17.0K | 5,754 | −3% | −<0.01% (now <0.01%) | filing |
| 2026-04-29 | Lewis Gregory P | Director | A | ▲ buy | 2,1110 | — | — | 5,961 | +55% | +<0.01% (now <0.01%) | filing |
| 2026-04-29 | Lee Joon Sup | Director | A | ▲ buy | 1,8030 | — | — | 1,803 | new | +<0.01% (now <0.01%) | filing |
| 2026-04-29 | Jellison William R | Director | A | ▲ buy | 1,4440 | — | — | 6,444 | +29% | +<0.01% (now <0.01%) | filing |
| 2026-04-29 | HOGAN RANDALL J | Director | F | ▼ sell | 2070 | $81.90 | $17.0K | 48,998 | −0.4% | −<0.01% (now <0.01%) | filing |
| 2026-04-29 | HOGAN RANDALL J | Director | A | ▲ buy | 2,1110 | — | — | 49,205 | +4% | +<0.01% (now <0.01%) | filing |
| 2026-04-29 | Groetelaars John P | Director | A | ▲ buy | 1,4440 | — | — | 1,444 | new | +<0.01% (now <0.01%) | filing |
| 2026-04-29 | Fonseca Lidia | Director | F | ▼ sell | 2070 | $81.90 | $17.0K | 7,644 | −3% | −<0.01% (now <0.01%) | filing |
| 2026-04-29 | Fonseca Lidia | Director | A | ▲ buy | 2,1110 | — | — | 7,851 | +37% | +<0.01% (now <0.01%) | filing |
| 2026-04-29 | DONNELLY SCOTT C | Director | F | ▼ sell | 2070 | $81.90 | $17.0K | 23,679 | −0.9% | −<0.01% (now <0.01%) | filing |
| 2026-04-29 | DONNELLY SCOTT C | Director | A | ▲ buy | 2,1110 | — | — | 23,886 | +10% | +<0.01% (now <0.01%) | filing |
| 2026-04-29 | Blomquist Denise L. | Officer (Chief Accounting Officer) | F | ▼ sell | 3180 | $81.90 | $26.0K | 13,262 | −2% | −<0.01% (now <0.01%) | filing |
| 2026-04-29 | Blomquist Denise L. | Officer (Chief Accounting Officer) | A | ▲ buy | 1,5080 | — | — | 13,580 | +12% | +<0.01% (now <0.01%) | filing |
| 2026-04-29 | ARNOLD CRAIG | Director | F | ▼ sell | 2070 | $81.90 | $17.0K | 42,185 | −0.5% | −<0.01% (now <0.01%) | filing |
| 2026-04-29 | ARNOLD CRAIG | Director | A | ▲ buy | 2,1110 | — | — | 42,392 | +5% | +<0.01% (now <0.01%) | filing |
Up to 200 most recent filings · select a heading to sort, or open “How to read this” above for definitions · this company on SEC EDGAR.